Denali Therapeutics Inc. (DNLI) Misses Q4 EPS by 6c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.86), $0.06 worse than the analyst estimate of ($0.80).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• The Fed is hiking. Why isn't UBS worried about stocks?
• Investec Double Upgrades Supreme Industries (SI:IN) to Buy